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Summary Tuberculosis (TB) remains a global emergency and is responsible for 1.7 million deaths annually.
Widespread global misuse of isoniazid and rifampicin over three decades has resulted in emergence of
the ominous spread of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB)
globally. These difficult to treat resistant forms of TB are increasingly seen in Asia, Eastern Europe,
South America and sub-Saharan Africa, disrupting TB and HIV control programmes. We review the
latest available global epidemiological and clinical evidence on drug-resistant TB in HIV-infected and
uninfected populations, with focus on Africa where data are scanty because of poor diagnostic and
reporting facilities. The difficult management and infection control problems posed by drug-resistant
TB in HIV-infected patients are discussed. Given the increasing current global trends in MDR-TB,
aggressive preventive and management strategies are urgently required to avoid disruption of global TB
control efforts. The data suggest that existing interventions, public health systems and TB and HIV
programmes must be strengthened significantly. Political and funder commitment is essential to curb the
spread of drug-resistant TB.
keywords tuberculosis, drugs, MDR-TB, XDR-TB, epidemiology, microbiology, treatment
Introduction
Efforts to control the global tuberculosis (TB) epidemic
have now been complicated by the emergence of strains of
Mycobacterium tuberculosis, which are resistant to one or
more anti-TB drugs. Multidrug-resistance originates from
misuse of anti-TB drugs by physicians, patients and
producers (Matteelli et al. 2007; Migliori et al. 2009)
(Figure 1). The identification and spread of multidrug-
resistant TB (MDR-TB) (Pablos-Me´ndez et al. 1998; Esp-
inal et al. 2001; Shah et al. 2005; WHO and IUATLD,
2008; Wright et al. 2009), and more recently, of exten-
sively drug-resistant TB (XDR-TB) globally (Holtz et al.
2005; Shah et al. 2005; Centers for Disease Control and
Prevention, 2006; WHO, 2010) is increasingly becoming a
major threat to achieving the projected goal of TB control
and elimination by the year 2050 as advocated by the
Millennium Development Goals (MDGs) and Stop TB
Partnership. This review discusses the clinical epidemiol-
ogy, microbiology, diagnosis, treatment and prevention
aspects of drug-resistant TB in HIV-infected and uninfected
adults globally, with special focus on MDR- ⁄XDR-TB in
resource-limited settings, with an emphasis on sub-Saharan
Africa because emerging clinical experience data shows
that drug-resistant TB is now more widespread than
previously thought.
Methods
A systematic review of all relevant publications on drug-
resistant TB was performed via a Medline search using the
key words ‘Tuberculosis’, ‘drug resistance’ ‘MDR-TB’ and
‘XDR-TB’, with the words ‘epidemiology, diagnosis,
treatment, drug resistance genes, TB control, epidemiol-
ogy, management, TB control programmes, Africa and
prevention’ covering the period 31st March 2000 to 1st
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April 2010, and all relevant literature from English
language medical journals were reviewed. In addition, the
US Centers for Disease Control and Prevention (CDC)
Morbidity and Mortality Weekly Report (MMWR) was
searched for reports on MDR-TB and XDR-TB published
from 2000 to the present and quoted in the review based
on priority criteria. Further sources of information were
data emerging from current studies and databases on
MDR- ⁄XDR-TB in South Africa, WHO publications on
TB and drug-resistant TB published over the past 15 years
(Schaaf & Zumla 2009) and relevant chapters from two
recently published textbooks on TB (Schaaf & Zumla
2009; Zumla & Schaaf 2009).
Definitions for drug-resistant TB
The definitions of drug-susceptible and drug-resistant TB
are given in Table 1. ‘Pan-susceptible TB’ is defined as TB
caused by Mycobacterium tuberculosis (M. tuberculosis)
strains that are susceptible to all first-line anti-TB drugs.
MDR-TB is defined as resistance to the two key first-line
anti-TB drugs, isoniazid (INH) and rifampicin (RMP/RIF)
(Pablos-Me´ndez et al. 1998; Espinal et al. 2001; WHO
and IUATLD, 2008; Wright et al. 2009; WHO, 2010). The
term XDR-TB appeared in the literature for the first time in
March 2006, in a report jointly published by WHO and
CDC, to describe a very aggressive form of disease
characterised by high mortality rates (Centers for Disease
Control and Prevention, 2006). It is presently defined as TB
caused by strains of M. tuberculosis, which are the
following: (a) resistant to at least INH and RMP (i.e.
MDR-TB), (b) plus any fluoroquinolone, and (c) to at least
Table 1 Definitions of Drug-susceptible and drug-resistant
tuberculosis (TB)
Pan (Totally)-susceptible TB
Tuberculosis caused by Mycobacterium tuberculosis strains
susceptible to all first-line anti-TB drugs.
INH Monoresistant TB
Tuberculosis caused by M. tuberculosis strains resistant only to
INH
Multidrug-resistant tuberculosis (MDR-TB)
Tuberculosis caused by M. tuberculosis strains resistant to at
least two first-line anti-TB drugs INH and rifampicin (RMP)
Extensively drug-resistant tuberculosis (XDR-TB)
Tuberculosis caused by M. tuberculosis resistant to RMP and
INH plus any fluoroquinolone, and at least one of the three
following injectable drugs: capreomycin, kanamycin or amikacin
Pan (Totally)-resistant TB
Tuberculosis caused by M. tuberculosis resistant to all first and
second-line anti-TB drugs
INH, isoniazid.
M. tuberculosis strains in the population 
Drug-susceptible M. tuberculosis 
community pool with occasional 
drug-resistant mutants 
INH Monotherapy or poor compliance 
INH Resistant M. tuberculosis 
strains get selected 
INH Resistant strains multiply 
Spontaneous RIF mutations occur 
in M. tuberculosis 
INH and RIF resistant strains multiply 
Multi-drug (RIF + INH) resistant      
M. tuberculosis strains proliferate
Figure 1 Evolution of multidrug resistance.
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one of three injectable drugs used in anti-TB treatment,
capreomycin, kanamycin or amikacin (Holtz & Cegielski
2007; Migliori et al. 2007).
Epidemiology of MDR-TB and XDR-TB
The latest data on the extent of drug-resistant TB are
summarised in the 2010 WHO MDR- ⁄XDR-TB Global
report on surveillance and response (WHO, 2010). The
proportions of MDR-TB among all new TB cases is shown
in Figure 2. MDR-TB caused an estimated 150 000 deaths
in 2008. The 2010 WHO report estimates that 440 000
MDR-TB cases occurred in 2008 (3.6% of the estimated
total incident TB episodes). Of these, 360 000 were among
new TB cases, and 94 000 were among individuals previ-
ously treated. Data on drug-resistant TB from Africa are
very scarce. India and China constitute approximately 50%
of the global burden of MDR-TB, followed by the Russian
Federation (9%). Eastern Europe and Central Asia have
reported very high proportions of MDR-TB among new
cases (Balabanova et al. 2005; Migliori et al. 2010). The
Russian Federation’s surveillance data from 12 of its oblasts
and republics reported proportions of 23.8–28.3% MDR-
TB among new TB cases in three of its oblasts in the north-
western part of the country.
Role of HIV in fuelling the drug-resistant TB epidemic
About 8% of all infections withM. tuberculosis occur in
people with HIV, making it the most important opportu-
nistic infection worldwide. Over the past two decades, the
HIV pandemic has been the most important factor for
increased numbers of TB cases being reported in sub-
Saharan Africa (Elliott et al. 1993; Habeenzu et al. 2007;
Kehinde et al. 2007; Umubyeyi et al. 2007; Meskel et al.
2008). The spread of the TB epidemic is closely related to the
highHIV infection rates in the general population. Recently,
co-infection of the two pathogens,M. tuberculosis andHIV,
has become more noticeable in Eastern Europe and in Asia
(Kingkaew et al. 2009). Sub-Saharan Africa bears the
burden of both very high TB incidence and the highest
human immunodeficiency virus (HIV) prevalence rates in
the world, and now represents 14% of the global burden of
new MDR-TB cases (Amor et al. 2008; WHO, 2010).
0 – <3 
3 – <6 
6 – <12 
12 – <18 
No data availablea
Subnational data only 
Australia, Democratic Republic of the Congo, Fiji, Guam, New Caledonia, 
Solomon Islands and Qatar reported data on combined new and previously
treated cases.
≥ 18
Figure 2 Global proportions of MDR-TB among new TB cases. [Reproduced with permission from WHO, (2010)]. MDR-TB,
multidrug-resistant tuberculosis.
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MDR-TB and XDR-TB in sub-Saharan Africa
There are scanty data about MDR-TB trends in Africa.
According to the 2010 Global WHO Report (WHO,
2010), only 22 of 46 countries of the African Region have
provided data on drug-resistant TB (12 having conducted a
nationwide survey since 2000 and 10 a sub-national level
survey). South Africa is the only country that collects
routine surveillance data. Thirty-four countries have
reported MDR-TB cases and eight XDR-TB cases. Only
three countries (Rwanda, the United Republic of Tanzania
and South Africa) have information on the proportion of
XDR-TB among MDR-TB cases. The reason why the
proportion of MDR-TB among patients with TB is
generally low in the African region (with a frequency
ranging from 0.5% to 3.9% among new TB cases and
0.0% to 16.7% among previously treated ones) is probably
related to poor laboratory facilities for drug susceptibility
testing (DST), poor surveillance mechanisms and reporting
procedures, outdated databases and sub-optimal coverage
of the infrequent surveys. Given the high incidence of TB
per population, the rates of MDR-TB cases arising per
100 000 population in some southern African countries are
predicted to be 5–6 times higher than those reported in
China and India. The latest WHO estimate of the number
of MDR-TB cases emerging in 2008 in Africa, most likely
an underestimate, is 69 000 cases (WHO, 2010).
Nine African countries rate among the 27 high-burden
MDR-TB countries with South Africa estimated to have
approximately 20 000 MDR-TB cases annually. Amor and
co-investigators based on data from 39 ⁄46 countries in
Africa estimate that MDR-TB is likely to be more prevalent
than previously recognised (Amor et al. 2008). Indeed,
more recent data indicate higher rates of MDR-TB in
several prevalence surveys. Recent surveys from Ethiopia
(retreatment cases) (Meskel et al. 2008), Nigeria (tertiary
hospital) (Kehinde et al. 2007), Zambia (prison) (Habe-
enzu et al. 2007) and Rwanda (retreatment cases) (Um-
ubyeyi et al. 2007) indicate MDR-TB prevalence rates of
26%, 54%, 9.5% and 9.4%, respectively. Alarming data
from Botswana suggest that notification rates of all cases of
TB and also of MDR-TB are increasing (Chirenda et al.
2009). If this reflects the situation in other high HIV-
prevalence countries where TB control programmes have
been destabilised, then the situation might be worse than
previously thought (Habeenzu et al. 2007; Kehinde et al.
2007; Umubyeyi et al. 2007; Amor et al. 2008; Meskel
et al. 2008; Chirenda et al. 2009; Kingkaew et al. 2009).
The lack of information on drug resistance in Africa will
impede planning of surveillance and activities of the
national TB and HIV programmes. Current estimates of
MDR-TB cases in many African countries are thus based
on mathematical modelling rather than actual studies.
Laboratory surveillance for MDR-TB and XDR-TB should
be strengthened and expanded across the region, particu-
larly where studies have never been carried out or data are
now older than 5 years. Three groups have recently
published their studies on the outcome of XDR-TB
treatment from South Africa (Gandhi et al. 2006; O’Don-
nell et al. 2009; Wright et al. 2009; Dheda et al. 2010;
Gandhi et al. 2010a,b). These studies, which are limited by
their restricted study design and not representative of the
general population, reveal that the drug resistance problem
in South Africa is more widespread than previously
thought and needs proper definition. It is evident that
urgent initiation and implementation of regular compre-
hensive and methodologically sound surveillance studies
from African countries are now needed to gauge the true
extent of the TB drug-resistant problem.
Microbiology of MDR-TB and XDR-TB
Drug-resistant TB is a microbiological diagnosis based on
susceptibility patterns of the M. tuberculosis strains iso-
lated from any patient clinical sample (Table 1). Multi-
drug-resistant M. tuberculosis strains are defined as those
that are resistant to INH and RMP. The frequency of
resistance to multiple drugs varies geographically, and
acquired (secondary) resistance is more common than
primary resistance. Drug resistance in M. tuberculosis is
because of the acquisition of mutations in chromosomally
encoded genes (Johnson et al. 2009).
The generation ofmultidrug-resistance inM. tuberculosis
is a consequence of accumulation of mutations primarily
because of inadequate or intermittent therapy or non-
compliance (Figure 1). Resistance to INH is because of
mutations in the katG gene, and about half of all isolates
with katG mutations have an amino acid replacement at
codon 315. The rpoB gene, which encodes the b-subunit of
RNA polymerase, harbours a mutation in an 81 -bp region
in about 95% of RMP-resistant M. tuberculosis strains
recovered globally. Mutations in the pncA gene can cause
pyrazinamide (PZA) resistance in approximately 70% of
clinical isolates. Approximately 65% of clinical isolates
resistant to ethambutol (EMB) have a mutation in the embB
gene. Clinical and genotypic characteristics of XDR-TB and
MDR-TB are now being studied. The following drug
resistance genes have been identified in second-line agents:
gyrA in flouroquinolones, rrs for aminoglycosides Kana-
mycin and Amikacin, inhS, othA and ethR for ethionamide,
alr and ddl for D-cycloserine and rrs for Capreomycin. The
genotypic characteristics ofM. tuberculosis isolates from
non-HIV-infected patients having MDR-TB and XDR-TB
evaluated by spoligotyping and the 24-locus mycobacterial
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interspersed repetitive units-variable number of tandem
repeats scheme showed that the Beijing genotype was the
most common genotype. The clinical features of patients
infected with the Beijing genotype and the drug resistance
profile of the Beijing genotype isolates were similar to those
for the non-Beijing family genotype.
The genotypic analysis of MDR-TB isolates shows that
commonly found mutations in drug-resistant isolates are
seen from different regions of the world. Transmission
chains can be defined by isolates having identical IS6110
DNA fingerprints, spoligotypes and mutations conferring
resistance. Molecular studies on mycobacterial strains can
give clues to nosocomial transmission of drug-resistant
M. tuberculosis strains. A study at King George V (KGV)
Hospital, in KwaZulu-Natal (KZN) (Pillay & Sturm 2010)
determined the role of nosocomial transmission of drug-
resistant TB in 26 patients infected with a new strain of
M. tuberculosis during treatment. DNA fingerprints 14 of
26 patients with differing isolates matched those of other
patients. Four acquired a F15 ⁄LAM4 ⁄KZN genotype, two
acquired fully susceptible Beijing strains. Three of the four
F15 ⁄LAM4 ⁄KZN strains were multidrug-resistant with
identical fingerprint patterns, while the fourth was fully
susceptible. One of these was acquired during hospitalisa-
tion and three after discharge. Both HIV-infected and non-
infected patients are at risk of infection with the
F15 ⁄LAM4 ⁄KZN strain in health care facilities and within
the community. There is a need for new diagnostic tests
(Wallis et al. 2010), which can rapidly identify drug-
resistant strains ofM. tuberculosis from clinical samples so
patients can be appropriately isolated to prevent nosoco-
mial transmission.
Clinical features of MDR-TB and XDR-TB
Clinical presentation, symptoms and signs
The clinical presentation, symptoms and signs of patients
with drug-resistant tuberculosis in the majority of cases do
not substantially differ from that of patients with TB
because of pan-susceptible M. tuberculosis strains (Gandhi
et al. 2006; O’Donnell et al. 2009; Schaaf & Dheda 2009).
Co-infection with HIV further complicates the clinical
picture because of other concomitant opportunistic infec-
tions (Dubrovina et al. 2008; Schaaf & Dheda 2009;
Gandhi et al. 2010; Grobusch 2010). In the early stages of
HIV infection, the clinical features of TB are similar to
those of HIV-uninfected patients. Clinical presentation
becomes more atypical with progressive immunosuppres-
sion. Drug-resistant TB should be suspected in patients
who fail to respond to the intensive phase of standard
short-course anti-TB therapy, or those who have: had TB
previously; a history of poor compliance and substance
abuse; been in contact with patients with drug-resistant
TB. At least half of the patients with drug-resistant TB have
none of these risk factors thus clinical awareness and a high
degree of suspicion are required.
Establishing a diagnosis of drug-resistant TB
Accurate and rapid diagnosis of drug-resistant TB is of
paramount importance for instituting appropriate clinical
management and appropriate infection control measures
(Schaaf & Dheda 2009; Wallis et al. 2010). The diagnosis
is usually suspected on clinical and radiological grounds,
and all health practitioners in high TB and HIV endemic
areas must have a high index of suspicion of drug-resistant
TB. The diagnosis of drug-resistant TB can only be
confirmed by molecular microbiological studies as
described earlier. When pulmonary TB is suspected clini-
cally in high TB and HIV ⁄AIDS endemic areas, other
pulmonary infections should be excluded. These include
Pneumococcus spp., Chlamydiae pneumoniae, Myco-
plasma spp., Legionelle spp., non-tuberculous mycobacte-
ria (e.g. Mycobacterium avium complex), Cryptococcus
spp., Histoplasma spp., cytomegalovirus, Aspergillus spp.,
Candida spp., and Pneumocystis jeroveci. Other non-
infectious complications also need to be considered such as
sarcoidosis, Kaposi’s sarcoma, lymphoproliferative dis-
eases and throe malignancies. The diagnostic steps in the
management of HIV-infected and HIV-uninfected patients
with drug-resistant TB are similar to those of drug sensitive
TB using conventional diagnostic algorithms. All
M. tuberculosis isolates should be subject to DST (Moore
et al. 2006; Pai et al. 2006; Hoek et al. 2008; Martin et al.
2008; Pietzka et al. 2009). This usually involves direct or
indirect DST in selective media using liquid or solid
culture, and this may take several weeks before results are
available. Furthermore, the costs of these tests are pro-
hibitive, and laboratory capacity and TB programme
budgets in African countries are severely limited. Recent
advances in molecular technology for DST have improved
our ability to rapidly diagnose MDR-TB and XDR-TB (Pai
et al. 2006; Wallis et al. 2010). Appropriate budgetary
investments into expansion of laboratory capacity to
rapidly diagnose drug-resistant TB and instituting treat-
ment quickly are now required.
Drug treatment of drug-resistant TB
When a diagnosis of MDR-TB is made, it gives the
attending physician another chance to cure the patient,
thus it is imperative that the best and most comprehensive
possible treatment regimen be used to successfully treat the
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patient. Failure to effectively treat the patient will lead to
further amplification of drug resistance leading to the
development of XDR-TB (Espinal et al. 2000; Espinal
2003; Quy et al. 2003; Chan et al. 2004; Saravia et al.
2005; Gandhi et al. 2010; Grobusch 2010). Patients with
MDR TB on treatment should be nursed in isolation until
sputum smear microscopy and cultures turn negative.
Close monitoring of the patient with DOTS and follow-up
is required after patient is discharged from the treatment
facility. Table 2 shows drug groups and treatment regi-
mens that are recommended for MDR and XDR in adults.
Table 3 shows the serious adverse events associated with
these drugs. Available first-line drugs comprise RMP, INH,
EMB, PZA and streptomycin (SM). INH and RMP are the
most potent of these drugs. Second-line drugs are amikacin,
capreomycin, cycloserine, linezolid, prothionamide, rifab-
utin and any of the flouroquinolones, e.g. moxifloxacin,
levofloxacin, ofloxacin, gatifloxacin. The treatment of
patients with MDR-TB and XDR-TB relies on drugs that
are less potent, need to be administered for a much longer
time and are substantially more toxic than those used to
treat TB caused by drug-susceptible strains. The cost of a
second-line drug regimen is much higher: up to thousands
of dollars compared to the cost of about US$ 20 per patient
for the standard 6-month short-course, first-line chemo-
therapy regimen (WHO Category 1). The optimal duration
Table 2 Drug groups for multidrug-resistant (MDR) and extensively drug-resistant (XDR-TB) tuberculosis treatment regimens for adults
[adapted from Schaaf and Dheda (2009)]
Drug group Drug name
Daily dosage in mg for adults (<33 kg – dose in mg ⁄ kg)
< 33 kg dose
in mg ⁄ kg 33–50 kg 51–70 kg
>70 kg (also
maximum
dose)
*Group 1: Oral first-
line drugs to which
the organism shows in
vitro susceptibility by DST
Ethambutol 25 800–1200 1200–1600 1600–2000
Pyrazinamide 30–40 1000–1750 1750–2000 2000–2500
Group 2: Second-
line injectable agents
(streptomycin is first-
line drug – not for use
in MDR ⁄XDR-TB)
Amikacin 15–20 500–750 750–1000 1000
Kanamycin 15–20 500–750 750–1000 1000
Capreomycin 15–20 500–750 750–1000 1000
Group 3: Fluoroquinolones Ofloxacin 15–20 800 800 800–1000
Levofloxacin 7.5–10 750 750 750–1000
Moxifloxacin 7.5–10 400 400 400
Group 4: Second-line oral
bacteriostatic agents
Ethionamide (or prothionamide) 15–20 500 750 750–1000
15–20 500 750 750–1000
Cycloserine (or terizidone) 15–20 500 750 750–1000
10–20 600 600 900
Para-aminosalisylic acid (PAS) 150 8 g 8 g 8–12 g
§Group 5: Drugs of
unclear use in drug-
resistant TB treatment
High-dose isoniazid 16–20
Linezolid 600 mg twice daily, but recent data suggest 300
mg twice daily or 600 mg or 300 mg may be
effective (see text – New drugs)
Amoxicillin ⁄ clavulanate Dosage for DR-TB not well defined. Normal
adult dose 875 ⁄ 125 mg twice daily or
500 ⁄ 125 mg three times daily. Higher dose
limited by adverse effects
Clarithromycin 500 mg twice daily
Thioacetazone 150 mg daily (Contraindicated in HIV-infected patients)
Imipenem ⁄ cilastatin Usual adult dose 500–1000 mg IV 6-hourly
DST, drug susceptibility testing.
*Cannot rely on DST – use as additional drug if DST result susceptible or not performed.
Choose one drug in each of these groups; amikacin preferred to kanamycin in children.
Choose one or more of these drugs to make up total of four new drugs.
§Consider use of these drugs if insufficient drugs to build an acceptable regimen with previous groups. Linezolid dosage for TB is still
uncertain. Thioacetazone should not be used in HIV-infected patients.
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of any given combination of anti-tuberculosis drugs for the
treatment of MDR-TB and XDR-TB has not been defined
yet (WHO, 2009). The effectiveness of third-line anti-TB
drugs (amoxicillin-clavulanate, clarithromycin, clofazimine
and linezolid, called Group 5 drugs in the WHO guide-
lines) remains undefined.
Failure of therapy and re-treatment regimens
Failure of therapy is associated with drug resistance, poor
drug compliance or insufficient treatment duration (Son-
nenberg et al. 2001; Korenromp et al. 2003; Migliori et al.
2002; Caminero 2008). Data from a large retrospective
cohort (>5550 cases) have provided evidence that standard
short-course chemotherapy, based on first-line drugs, was
inadequate to treat patients with MDR-TB (Espinal et al.
2000). A 6-year follow-up study from Taiwan found that
patients treated with quinolone-containing second-line
regimens were significantly less likely to relapse than those
treated with first-line drugs (Chiang et al. 2006). The
Category II re-treatment (regimen 2: INH-EMB-RMP-
PZA-SM) ⁄1(INH-EMB-RMP-PZA) ⁄5(INH-EMB-RMP)
recommended by WHO is inadequate for settings with a
high proportion of MDR-TB patients among those failing a
Category I regimens (Sonnenberg et al. 2001; Migliori
et al. 2002; Espinal 2003; Korenromp et al. 2003;
Table 3 Important adverse effects of sec-
ond-line anti-tuberculosis drugsSecond-line drug Adverse clinical effect* Tests to monitor routinely
Amikacin
Kanamycin
Capreomycin
Ototoxicity (cumulative
dose important)
Nephrotoxicity
Audiology (hearing test) –
monthly if possible
Serum creatinine and
potassium levels – monthly,
high-risk patients more often
Fluoroquinolones Gastrointestinal disturbance
Insomnia
Arthralgia
Clinical observation
Serum uric acid if used
with pyrazinamide
Ethionamide
(or protionamide)
Gastrointestinal disturbance
Hepatotoxicity
Hypothyroidism
Clinical observation.
Prevent by initially
splitting dose or increasing
dose (drug ramping)
Jaundice – serum alanine
transferase and bilirubin
Thyroid-stimulating
hormone levels (free T4) –
at least 6-monthly
Cycloserine
(or terizidone)
Psychosis, seizures,
paresthesia, depression
Clinical observation –
all patients to receive
preventive pyridoxine
Para-aminosalisylic
acid (PAS)
Gastrointestinal disturbance
Hypothyroidism
Clinical observation
Thyroid-stimulating
hormone levels (free T4) –
at least 6-monthly
Linezolid Myelosuppression or
thrombocytopenia
Lactic acidosis
Peripheral neuropathy
Pancreatitis (Abdominal pain)
Optic neuritis
Drug interaction with MAOIs
Full blood count
and platelets – weekly
at first then monthly
Serum lactate level
Symptoms of tingling
and numbness
Clinical and serum
amylase as indicated
Vision testing
Exclude use of monoamine
oxidase inhibitors
*Adverse effects of first-line dugs and antiretroviral drugs in HIV-infected patients often
have overlapping adverse effects.
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Quy et al. 2003; Saravia et al. 2005; Caminero 2008).
Treating MDR-TB patients using Category II regimens also
runs the risk of further amplification of drug resistance
(Caminero 2008). Hence, the common practice in high-
burden settings, in the absence of susceptibility data, to
replace standard first-line treatment (regimen 1) with an
extended treatment regimen containing SM (regimen 2) in
patients failing first-line treatment, translates into adding a
single drug to a failing regimen. To prevent the amplifica-
tion of drug resistance, all re-treatment cases, and those
failing a first-line regimen, should have their mycobacterial
isolates screened by DST for RMP and INH resistance.
A number of basic rules for the management of these
patients have been agreed upon recently (Ghandi et al.
2010b). The recommended regimen involves combination
of a minimum of four drugs to which the M. tuberculosis
isolate is likely to be susceptible (more than four could be
necessary if four susceptible drugs are not available or if it
is necessary to use some drugs belonging to group 5), the
choice being based on a stepwise adoption through the five
groups of anti-TB drugs categorised by order of efficacy,
safety and costs (Table 2). The duration of the intensive
phase, when an injectable agent is administered, should be
at least 6 months (4 months after culture conversion). The
continuation phase (without the injectable drug) should be
prolonged until 18 months after culture conversion (Sotgiu
et al. 2009). Recent data from South Africa suggest that
XDR-TB patients with ofloxacin-resistant isolates fared
better when treated with moxifloxacin, compared to XDR-
TB patients who did not receive moxifloxacin (Dheda et al.
2010). Although the optimal duration of treatment for
MDR and XDR-TB is not known, a minimum of
18 months after the first negative culture (or 24 months for
XDR-TB) is usually recommended (Schaaf & Dheda 2009).
MDR ⁄XDR-TB patients are often hospitalised during the
intensive phase of treatment or, in the case of XDR-TB,
until they become culture-negative. Latest data from South
Africa show that XDR-TB is not associated only with
HIV-infected individuals (Dheda et al. 2010). Treating
HIV-infected XDR-TB patients with appropriate anti-TB
regimens and with Highly Active Antiretroviral Therapy
(HAART) has lower mortality compared to untreated
patients, and survival in HIV-infected patients is better than
that previously reported. Because current management
outcomes of XDR-TB patients in South Africa are poor,
prevention of XDR-TB and early detection and manage-
ment of MDR-TB and XDR-TB through programmatic and
laboratory capacity strengthening remain an important
priority for high TB and HIV ⁄AIDS endemic areas.
Treatment monitoring for drug-resistant TB
Treatment monitoring is performed to evaluate early
predictors of treatment outcome (sputum smear and
culture conversion) and to ensure prevention and eventu-
ally timely management of adverse events of treatment. In a
recent review on XDR-TB (Sotgiu et al. 2009), only three
(23%) of the 13 studies included in the review evaluated
both median time to sputum smear and culture conversion,
while four measured the median time to culture conver-
sion. Longer treatment duration and delayed sputum smear
conversion were reported in most studies among XDR-TB
patients. Median time to sputum smear conversion ranged
from 41 to 56 days in MDR-TB patients, while it ranged
from 88 to 110 days in XDR-TB cases. The median time to
culture conversion ranged from 58 to 99 days in MDR-TB
cases; it was substantially different in XDR-TB patients,
ranging from 60 to 195 days. In a recent study from South
Africa, the culture conversion rate in XDR-TB patients was
< 20% and of those who converted, 70% did so within
6 months of initiating treatment (Dheda et al. 2010).
Risk factors and treatment outcomes of MDR-TB
There have been several published reports on the treatment
outcomes of MDR-TB treated with second-line drugs but
methods used to assess outcome varied. Some focused on
efficacy of treatment and reported only those who had
adequate adherence to treatment and sufficient follow-up
data. This approach may have overestimated the propor-
tion of patients with a successful outcome (Goble et al.
1993; Park et al. 1998; Chan et al. 2004). Others reported
outcome of the whole cohort of patients without excluding
any cases from outcome analysis (Flament-Saillour et al.
1999; Kim et al. 2001). Laserson et al. (2005) proposed
standardised definitions for outcome of MDR-TB
Key messages on multidrug-resistant (MDR-TB) and extensively
drug-resistant (XDR-TB) tuberculosis
WHO estimates that 440 000 MDR-TB cases occurred globally in
2008 and the spread of MDR-TB now threatens gains made in TB
control
Recent data from South Africa show MDR-TB and XDR-TB are
important causes of death in both HIV-infected and HIV-non-
infected individuals
Drug-resistant TB should be suspected in patients who fail to
respond to the intensive phase of standard short-course therapy,
have had TB previously, have a history of poor compliance, are
known contacts of patients with drug-resistant TB.
WHO infection control guidelines must be carefully followed to
prevent community and nosocomial transmission of drug-resis-
tant TB.
Drug-resistant TB requires serious attention from health
personnel, governments, policy makers and funders to bring it
under control
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treatment,whichhave enabled international comparisonbut
the definition of treatment has not yet been standardised
(Chiang et al. 2009). Nevertheless, it is clear that defaulting
is one of the major challenges in the treatment of MDR-TB.
Risk factors for adverse treatment outcome in patients
with MDR-TB and XDR-TB have been recently reviewed
in detail (Dheda et al. 2010; Gandhi et al. 2010; Grobusch
2010). They include delayed treatment initiation, prior
treatment with anti-tuberculosis drugs, use of fewer
second-line drugs in a regimen, previously treatment with
second-line drugs, prior exposure to fluoroquinolones,
resistance to fluoroquinolones or to capreomycin, low
BMI, HIV-seropositivity and other immunosuppressive
conditions. Treatment outcome of MDR-TB patients from
resource-limited settings reported cure rates of 60–75%
(O’Donnell et al. 2009). The proportion of MDR-TB
patients who were successfully treated ranged from 77%
among new cases to 69% among previous treated patients.
A recent report has confirmed that XDR-TB had higher
probability of death, longer hospitalisation, longer treat-
ment duration and delayed microbiological conversion
when compared to MDR-TB at TB reference centres in
Italy and Germany (Migliori et al. 2007). Earlier observa-
tions from the Tugela Ferry outbreak in the Republic of
South Africa that XDR-TB is untreatable have not been
confirmed in other areas of the world where HIV was not a
big problem (Gandhi et al. 2010). A recent systematic
review on MDR-TB and XDR-TB, including studies from
North and South America, Europe and Korea (Sotgiu et al.
2009), has shown that XDR-TB can be successfully treated
in more than 50% of patients. However, treatment
duration is significantly longer, and outcomes are in
general poorer than for non-XDR-TB patients.
Our latest data from South Africa demonstrated in a
large cohort of XDR-TB cases (n = 220, 43% being
HIV-seropositive) that the overall mortality was 36%, was
similar in HIV-positive and HIV-negative individuals, but
significantly lower in HIV-positive patients not treated
with antiretroviral therapy compared to those who were
(Dheda et al. 2010). Thus, overall treatment-related out-
comes of XDR-TB were generally poor. This may be
related to several factors operating in resource-poor
settings, such as the high proportion of patients with prior
MDR-TB, malnutrition, re-infection and strain dynamics,
among other factors.
Surgical treatment for MDR-TB and XDR-TB
The role of surgery in the management of extensive
pulmonary involvement in MDR- ⁄XDR-TB remains con-
troversial (Torun et al. 2007; Dravniece et al. 2009).
Surgical resection of infected lung tissue has been reported
to be a useful strategy in the treatment of MDR-TB and
XDR-TB. While some studies reported that surgery was
associated with a better outcome (Chiang et al. 2001;
Somocurcio et al. 2007), others found no additional benefit
of surgery in the treatment of MDR-TB (Torun et al. 2007).
The contribution of surgical intervention may be useful
when medical treatment fails to clear sputum mycobacteria
(Chiang et al. 2001; Dravniece et al. 2009). Surgical
intervention is usually indicated for extensive drug resis-
tance with a high probability of failure of medical therapy
alone (Iseman et al. 1990;Motus et al. 2006), but its timing
is not yet well defined. Surgical intervention depends on the
following two factors: (1) localised lung disease with good
chances for complete or nearly complete resection and
adequate expected post-operative lung function, and (2)
susceptibility ofM. tuberculosis isolate to anti-TB drugs to
ensure post-surgery stump healing (Iseman et al. 1990).
Effective anti-tuberculosis treatment offered for at least
3 months prior to the surgical intervention to reduce
bacillary load is recommended (Iseman et al. 1990).
Surgical interventions complementing individualised che-
motherapy regimens guided by DST have led to treatment
success rates in selected MDR-TB patients of >90% in a
number of studies, but success rates in patients with
XDR-TB are lower. A study from Ekaterinburg (Russian
Federation) evaluated the outcomes of 214 culture-
confirmed patients with cavitary pulmonary TB (79.9% of
them beingMDR): 109 underwent artificial pneumothorax,
and 105 were treated with chemotherapy only (Motus et al.
2006). Among new cases, those who had artificial pneu-
mothorax had a higher proportion of sputum smear
conversion than controls (100% vs. 70.9%; P < 0.01).
Similarly, among retreatment cases, the proportion of
smear conversion was, respectively, 81% among cases vs.
40% among controls (P < 0.01). The time to conversion
was also faster in group than in control cases (Motus et al.
2006). Further studies are necessary to evaluate the role of
artificial pneumothorax in treating MDR- ⁄XDR-TB cases.
Public health responses to drug-resistant TB epidemic
Infection control measures and recommendations
WHO policy on TB infection control in health care settings
and households has been clearly defined (WHO, 2009).
This covers organisational activities (surveillance and
assessment at all levels of the health system), administrative
controls (triage, cough etiquette, reduction in unnecessary
hospital stay, among others), environmental controls
(natural ventilation, mechanical ventilation, ultra-violet
irradiation and health facility renovation) and personal
protection. Personal protection includes both the use of
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respirators for health staff and masks for patients on one
side and the ‘Package of prevention and care for health care
workers’ on the other side [including HIV prevention,
antiretroviral therapy (ART) and INH preventive therapy
for HIV-positive health care workers].
Tuberculosis infection control measures in most health
care facilities in the developing countries are virtually non-
existent because of poor investment by governments into
their health systems and TB programmes (Kranzer et al.
2010). Implementation of comprehensive infection control
measures is not usually feasible, but implementing simple
triage systems to separate potentially infectious (coughing)
patients, and providing masks to patients and ⁄or staff
could be easily carried out. Ideally, patients with drug-
resistant TB must be cared for in hospitals equipped with
negative pressure isolation facilities, administrative hospi-
tal protocols to deal with such patients and appropriate
environmental protective measures should be taken. Ade-
quate ventilation (>12 air changes ⁄h) obtained by opening
windows and doors is the most important and easily
implemented measure other than diagnosing and treating
infectious cases early and effectively and separating
suspected cases from other susceptible people such as
children and HIV-infected individuals. Cough etiquette is
also a cost-effective intervention that needs to be imple-
mented at all levels. A recent modelling study on infection
control outcomes estimated that half of anticipated XDR-
TB cases could be averted by applying a combination of
available strategies in developing countries (WHO, 2009).
Appropriate safety measures using negative pressure cate-
gory 3 cabinets, masks and gloves should be implemented
by laboratory staff when dealing with biological samples
from patients suspected of having drug-resistant TB strains.
Contact tracing of workmates and family members for
drug-resistant TB
By the time a patient is diagnosed with drug-resistant TB,
most of his ⁄her contacts will have been infected. Both
hospital and community-based health care workers are at
risk of acquiring drug-resistant TB (Kranzer et al. 2010).
Contact tracing is one of the most fundamental measures
to detect active cases of TB, and these services must be
aligned to all health services. Everyone diagnosed with
drug-resistant TB must be isolated, and infection control
procedures described earlier should be followed.
Importance of proper implementation of TB programme
control measures to control drug-resistant TB
There are only a limited number of treatment options for
drug-resistant TB because the numbers of safe and effective
TB drugs are few. An urgent and comprehensive TB
programme response to the drug-resistant TB epidemic is
required to tackle a grave situation, which threatens to
derail gains made in TB control. The extent of MDR-TB
and XDR-TB in areas of high HIV prevalence needs to be
defined. Laboratory capacity (trained staff and appropriate
equipment) needs to be established to undertake DST to
facilitate rapid diagnosis of drug resistance. The HIV ⁄AIDS
epidemic continues to generate large numbers of TB cases,
and the close association between the two diseases poses
major challenges to TB and HIV control programmes of all
developing countries (Lalloo & Pillay 2008; Abdool Karim
et al. 2009). There is an urgent need for government
national TB programmes to synergise their activities with
HIV ⁄AIDS programmes and ensure that control methods
that are known to work are implemented. TB and HIV
programmes must be aligned together and their capabilities
strengthened to improve diagnostic capabilities, improved
treatment rates and monitoring of drug-resistant TB.
Priorities for HIV-infected patients with TB are improved
case detection rates, HIV screening procedures, initiating
antiretroviral therapy and INH prophylactic therapy as
appropriate, increasing treatment completion rates, accu-
rately diagnosing drug-resistant cases by introducing the
latest available technologies for rapid detection, effectively
treating drug-resistant cases, implementing effective con-
tact tracing and infection control measures. TB control
programmes are dependent on the health systems they are
part of and governments should wake up to the emergency
that drug-resistant TB poses. They must ensure that greater
emphasis is given to diagnosing and treating patients with
TB and TB ⁄HIV ⁄AIDS based on existing principles of TB
care.
Global recommendations for prevention and control
of drug-resistant TB
In 2007, pressed by the emerging threat represented by
MDR-TB and XDR-TB, WHO formulated a policy to
address this epidemic at the global level (Shah et al. 2005;
WHO and IUATLD, 2008; WHO, 2010). The major
recommendations formulated by the expert panel were (i)
to improve the ‘quality’ of TB control globally to prevent
the selection of MDR-TB and XDR-TB mutants, and (ii) to
further improve the organisation of early diagnosis and
effective treatment of the existing cases. WHO developed a
broader approach, known as the new Stop TB Strategy,
built upon the existing well-known DOTS strategy as the
element of continuity. The new strategy is composed of six
elements: (1) pursue high-quality DOTS expansion and
enhancement; (2) address TB ⁄HIV, MDR-TB and other
challenges; (3) promote health system strengthening; (4)
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engage all care providers; (5) empower people with TB and
communities; and (6) enable, promote and fund research.
Recent advances in rapid diagnostics and treatment
for drug-resistant TB
New technological advances for rapid diagnostics for
MDR-TB
Current DST testing laboratory methods take a few weeks
before the results are available; the need for rapid
identification of drug-resistant TB is great. Newer molec-
ular-based diagnostic technologies for rapid identification
of drug-resistant genes from patient sputum samples, albeit
very expensive presently, have been recently introduced
(Pillay & Sturm 2010; Wallis et al. 2010). These show
promise for early diagnosis and rapid institution of
effective chemotherapy. This would improve management
and cure rates of patients with drug-resistant TB. This will
also allow for national TB programmes to improve MDR-
TB surveillance, notification and instituting infection
control. They include Gene Xpert (Cepheid), the line probe
assays (e.g. Hain MDRplus assay and InnoLip assay) and
the mycobacteriophage assays. For identification of drug
resistance, bacteriophage amplification assays have shown
high specificity and sensitivity in culture M. tuberculosis
isolates, but evidence is lacking for their use on clinical
specimens. Gene Xpert is a user-friendly ‘closed’ system
nested real-time PCR assay that enables a rapid confir-
mation of TB and also simultaneously determines suscep-
tibility to RMP. Formats to detect resistance to other drugs
are under development. The line probe assays amplify a
resistance-containing gene segment, e.g. the rpoB gene
‘hotspot’, and the PCR products are hybridised to oligo-
nucleotide probes on a nitrocellulose strip (line probe; this
is an ‘open’ system) (Pai et al. 2006). A variation, the Hain
MDRplus sl version, can rapidly detect resistance to
several drugs. There are several studies currently evaluat-
ing these technologies at research field sites in high
endemic TB areas. If found to be useful, the cost of these
machines will drop to affordable levels as sales increase
and donor funding is justified.
Cheaper alternative technologies for diagnosis of drug-
resistant TB
There are other accurate and cheap alternative methods
described for use in resource-poor settings, and drug
susceptibility results are often available within 2–3 weeks.
These include microscopic observation DST (MODS),
which relies on identifying the characteristic cording of
M. tuberculosis in liquid medium using an inverted light
microscope (Moore et al. 2006). The main drawback is
that it is labour intensive. Thin-layer agar microscopically
detects early growth of M. tuberculosis on a thin layer of
agar; the platform can be simplified and standardised to
detect resistance on colorimetric grounds. The nitrate
reductase assays rely on a M. tuberculosis produced
nitrite-induced colour change (Griess reaction) to detect
growth in selective media (Martin et al. 2008). Novel
approaches include the high resolution melt assay, which is
able to identify clinical isolates harbouring mutations
conferring RMP resistance by comparing DNA melt
profiles of their RMP resistance determining region to the
DNA melt profiles of a wild type standard (Hoek et al.
2008; Pietzka et al. 2009). The challenge is now to
determine how these technologies will perform in high and
low-burden MDR-TB settings, what impact they may have
on outcomes, and how best to combine them with existing
low cost diagnostic tools in high-burden settings. Several
studies are ongoing at present evaluating how the Hain
MDRplus assay performs when included as early as
possible in diagnostic algorithms in high TB incidence, low
income countries.
Newer anti-TB drugs pipeline and drug regimens
The Global Alliance for TB drug development has a
number of drugs in the pipeline. These will soon be
evaluated in good clinical practices (GCP) randomised
controlled clinical trials for their to shorten the duration
of anti-TB chemotherapy, to test their effectiveness for use
in patients with drug-resistant TB (Lienhardt et al. 2010;
Ma et al. 2010). The diarylquinoline Tibotec Medical
Compound (TMC)207, which has a unique mode of
action inhibiting mycobacterial ATP synthase, showed
delayed bactericidal activity in early bactericidal activity
studies in new patients with TB, with no serious TMC207
related adverse effects. Other promising bactericidal and
potentially sterilising compounds currently evaluated in
phase 1 trials and Early Bactericidal Activity (EBA)
studies are the two nitroimidazoles, PA-824 (nitroimi-
dazo-oxazine) and OPC-67683 (dihydroimidazo-oxazole),
sudoterb (pyrrole LL-3858 and an EMB derivative
(diamine SQ109). The process from drug discovery, safety
and pharmacokinetic studies to phase I, I, III studies takes
nearly 20 years before a product comes into the market.
A new initiative called ‘Critical Path to TB Regimens’
(CPTR) consisting of industrial, funder and NGOs part-
ners aims to drastically reduce the amount of time needed
to register novel drug regimens for treatment of all forms
of TB (TB Alliance, 2010). It is important that clinicians
and public health officers are regularly updated on all
new developments in this area.
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Potential immunotherapies for drug-resistant TB
The sub-optimal treatment outcomes currently achieved
for XDR-TB and MDR-TB cases call for innovative new
strategies to increase treatment effectiveness. Adjunct
immunotherapy to drug treatment has been discussed for
some time now. The aim of immunotherapy is to ‘realign’
or improve the immune response by either promoting
protective (Th1) immunity or blocking harmful immune
(Th2) responses. Currently available immunotherapeutic
agents can be divided into three categories: immunoregu-
latory approaches, immunosuppressive therapy and sup-
plement effector cytokines.
Immunoregulatory approaches are seeking to alter the
nature of the immune response (Churchyard et al. 2009).
They can be divided into three sub-groups, those for which
(i) good manufacturing practices (GMP) manufacturing
capacity exists (High dose IVIg, HE2000-16a-bromoepi-
androsterone, multidose heat-killedMycobacterium vaccae
or Mycobacterium w, anti-IL-4), those for which (ii) GMP
manufacturing capacity can be established [DNA vaccine
(HSP65)] and (iii) the others (Dzherelo, SCV-07 SciCLone,
RUTI).
Immunosuppressive therapy seeks to increase access of
antibacterial drugs, or their susceptibility to them. They
include thalidomide (lowering TNF levels), etanercept
(blocking TNF) and prednisolone (having a broad
anti-inflammatory effect). Supplement effector cytokines
are aimed at enhancing the anti-microbicidal activity of
the existing drugs. They include recombinant human (rh)
IFN-gamma and rh-IFN-gamma, rh-IL-2, rh-granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-
12. Studies are being planned to evaluate the use of
adjunct immunotherapy (e.g. multiple doses of either
M. vaccae, M. w or IVIG) for the treatment of MDR-TB
and XDR-TB patients. They will be conducted in parallel
involving study cohorts in South Africa and Eastern
Europe. As this is a novel area, it will be several
more years before efficacy data are available and
included (if proven to be effective) in programmatic
management of MDR-TB and XDR-TB cases in
resource-limited settings.
Global efforts to tackle MDR-TB and XDR-TB
Further key steps in the fight against MDR-TB and XDR-
TB are documented by the Global MDR-TB and XDR-TB
Response Plan and the outcomes of the governmental
conference organised in China in April 2009 to develop the
Beijing Call for Action (World Health Organization,
2007). The document committed the 27 high-MDR-TB
burden countries to undertake a specific set of actions for
MDR-TB and XDR-TB containment and prevention.
Recommendations for increased investment by national TB
Programmes in HIV ⁄TB endemic areas are as follows:
(1) Preventing XDR-TB through basic strengthening and
alignment of TB and HIV programmes by increasing
case detection and effective treatment of drug sensitive
TB. The new Stop TB strategy and the Global Plan to
Stop TB are the key reference documents to guide
these priority interventions.
(2) Improving management of individuals suspected to be
affected by MDR-TB and XDR-TB through acceler-
ated access to laboratory facilities with rapid DST test
for RMP and INH resistance, DST for MDR-TB cases
and improved detection of cases suspecting of har-
bouring MDR strains both in high and in low HIV
prevalence settings.
(3) Strengthening management of MDR and XDR-TB
and treatment design in both HIV-negative and
positive individuals, through adequate use of second-
line drugs and patient-centred approaches to ensure
support and supervision.
(4) Standardising the definition of MDR-TB and XDR-
TB.
(5) Increasing contact tracing and screening.
(6) Health care worker infection control and protection
mainly (but not exclusively) in high HIV prevalence
settings.
(7) Implementing immediate MDR-TB and XDR-TB
surveillance activities.
(8) Initiating advocacy, communication and social mo-
bilisation activities to inform and raise awareness
about TB and drug-resistant TB.
Within the framework of these recommendations,
USAID in collaboration with WHO and other partners has
developed a tool (known as ‘MDR ⁄XDR-TB Assessment
and Monitoring Tool’) to be used for (i) preparing national
or sub-national plans for MDR ⁄XDR-TB prevention and
control; (ii) providing baseline information and monitoring
progress; (iii) providing data and analysis to prepare Green
Light Committee (GLC) and Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) applications; (iv)
providing information to guide requests for external
technical assistance; and (v) providing information to
guide donor investment in MDR- ⁄XDR-TB interventions.
This suggests that using existing interventions,
public health systems and TB and HIV programmes must
be strengthened significantly, and political and funder
commitment is essential to curb the spread of
drug-resistant TB.
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